The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)

被引:17
作者
Jung, Susanne [1 ]
Wermker, Kai [1 ]
Poetschik, Harald
Ziebura, Thomas [2 ]
Kleinheinz, Johannes [1 ]
机构
[1] Univ Hosp Muenster, Res Unit Vasc Biol Oral Struct VABOS, Dept Craniomaxillofacial Surg, D-48149 Munster, Germany
[2] Univ Hosp Muenster, Dept Orthodont, D-48149 Munster, Germany
来源
HEAD & FACE MEDICINE | 2010年 / 6卷
关键词
PERMEABILITY FACTOR; TUMOR; ANGIOGENESIS; EXPRESSION; CANCER; HEAD; RECEPTORS; SERA;
D O I
10.1186/1746-160X-6-29
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Hyperbaric oxygen (HBO) therapy is an effective adjunct treatment for ischemic disorders such as chronic infection or chronic wounds. It combines hyperoxic effects with the stimulating potential of post-therapeutic reactive hypoxia. As its crucial effects, stimulation of fibroblast growth, induction of collagen synthesis and the initiation of angiogenesis are discussed. Angiogenesis is a multistage process resulting in the growth of blood vessels. It includes degradation of extracellular matrix, proliferation and migration of different cell populations and finally formation of new vessel structures. This complex chain of procedures is orchestrated by different cytokines and growth factors. Crucial mediators of angiogenesis are basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF); their in-vivo function is still not fully understood. Methods: Forty-three patients suffering from sudden sensorineural hearing loss or tinnitus were treated with HBO. The therapy included 10 sessions of 90 minutes each, one session a day. Serological levels of bFGF and VEGF were assessed by enzyme-linked immunosorbent assays performed according to the manufacturer's instructions on day 1, 2, 5 and 10 of HBO therapy and were compared to mean values of the control group, related to the patient's age and sex, and their development observed over the ten days of HBO. Results: There was no sex-or age dependency of bFGF observed in the present study, whereas under HBO our results showed a significant mitigation of the bFGF concentration. In the present data, there was no connection between the VEGF concentration and the patients' ages. Women showed significantly higher levels of VEGF. There was no significant change of VEGF concentration or the VEGF/bFGF ratio during HBO. All scored results varied within the range of standard values as described in the current literature. Conclusions: A significant effect of HBO on serum concentrations of bFGF and VEGF was not verified in the present study. Additional application of exogenous growth factors in conjunction with HBO was not obviously linked by a coherent cause-and-effect chain as far as wound healing is concerned.
引用
收藏
页数:5
相关论文
共 29 条
  • [1] SYNERGISTIC EFFECT OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND BASIC FIBROBLAST GROWTH-FACTOR ON ANGIOGENESIS IN-VIVO
    ASAHARA, T
    BAUTERS, C
    ZHENG, LP
    TAKESHITA, S
    BUNTING, S
    FERRARA, N
    SYMES, JF
    ISNER, JM
    [J]. CIRCULATION, 1995, 92 (09) : 365 - 371
  • [2] Brattström D, 1998, ANTICANCER RES, V18, P1123
  • [3] Camporesi RM, 1996, HYPERBARIC OXYGEN TH
  • [4] Dellacono FR, 1997, AM J SURG, V174, P540
  • [5] Dietz A, 1999, HNO, V47, P695, DOI 10.1007/s001060050447
  • [6] Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
    Dirix, LY
    Vermeulen, PB
    Pawinski, A
    Prove, A
    Benoy, I
    DePooter, C
    Martin, M
    VanOosterom, AT
    [J]. BRITISH JOURNAL OF CANCER, 1997, 76 (02) : 238 - 243
  • [7] EXOGENOUS VASCULAR ENDOTHELIAL GROWTH-FACTOR INDUCES MALFORMED AND HYPERFUSED VESSELS DURING EMBRYONIC NEOVASCULARIZATION
    DRAKE, CJ
    LITTLE, CD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) : 7657 - 7661
  • [8] The biology of vascular endothelial growth factor
    Ferrara, N
    DavisSmyth, T
    [J]. ENDOCRINE REVIEWS, 1997, 18 (01) : 4 - 25
  • [9] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [10] FOLKMAN J, 1988, AM J PATHOL, V130, P393